The Barriers to Uniform Implementation of Clinical Practice Guidelines (CPG) for Thyroid Cancer

  • Ujjal K. Mallick
  • Fabián Pitoia


Clinical Practice Guidelines (CPGs) provide recommendations about the current best practice likely to offer the best outcome based upon the most reliable scientific evidence available at the time, for relevant professionals, patients, and policy makers of healthcare organizations. National CPGs thus aim to standardize high quality care amongst all professionals, specialist units and hospitals of the country by reducing the variation and heterogeneity in practice.


Clinical practice guidelines (CPGs) Variation in uniform implementation between thyroid cancer units in the same country as well as between different countries Adapting guidelines to local needs Generic causes of variation Thyroid cancer CPG specific factor which might lead to such variation Lack of trials and studies Relative lack of high quality evidence and strong recommendations in CPGs Many areas of uncertainty and clinical equipoise Variable interpretation by professionals and patients Need for more international collaboration High quality international trials and studies Effective Cost effective User friendly CPG’s with international perspective Professional and patient education and support Patient-doctor partnership to help CPG implementation 



F Pacini (Italy), J Brierley (Canada), C S Bal (India), B Haugen (USA).


  1. 1.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.CrossRefGoogle Scholar
  2. 2.
    Haymart MR, Banerjee M, Yang D, Stewart AK, Sisson JC, Koenig RJ, Doherty GM, Griggs JJ. Variation in the management of thyroid cancer. J Clin Endocrinol Metab. 2013;98(5):2001–8.CrossRefGoogle Scholar
  3. 3.
    Famakinwa OM, Roman SA, Wang TS, Sosa JA. ATA practice guidelines for the treatment of differentiated thyroid cancer: were they followed in the United States? Am J Surg. 2010;199(2):189–98.CrossRefGoogle Scholar
  4. 4.
    Harrison MB, Graham ID, van den Hoek J, Dogherty EJ, Carley ME, Angus V. Guideline adaptation and implementation planning: a prospective observational study. Implement Sci. 2013;8:49–63.CrossRefGoogle Scholar
  5. 5.
  6. 6.
    Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, Gilbert J, Harrison B, Johnson SJ, Giles TE, Moss L, Lewington V, Newbold K, Taylor J, Thakker RV, Watkinson J, Williams GR, British Thyroid Association. Guidelines for the management of thyroid cancer. Clin Endocrinol. 2014;81(Suppl 1):1–122.CrossRefGoogle Scholar
  7. 7.
    Phillips AW, Fenwick JD, Mallick UK, Perros P. The impact of clinical guidelines on surgical management in patients with thyroid cancer. Clin Oncol (R Coll Radiol). 2003;15(8):485–9.CrossRefGoogle Scholar
  8. 8.
    Likhterov I, Tuttle RM, Haser GC, Su HK, Bergman D, Alon EE, Bernet V, Brett E, Cobin R, Dewey EH, Doherty G, Dos Reis LL, Klopper J, Lee SL, Lupo MA, Machac J, Mechanick JI, Milas M, Orloff L, Randolph G, Ross DS, Rowe ME, Smallridge R, Terris D, Tufano RP, Urken ML. Improving the adoption of thyroid cancer clinical practice guidelines. Laryngoscope. 2016;126(11):2640–5.CrossRefGoogle Scholar
  9. 9.
    Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: National Academies Press (US); 2001.Google Scholar
  10. 10.
    Mehra S, Tuttle RM, Bergman D, Bernet V, Brett E, Cobin R, Doherty G, Klopper J, Lee S, Machac J, Milas M, Mechanick JI, Orloff L, Randolph G, Ross DS, Smallridge R, Terris D, Tufano R, Alon E, Clain J, Dos Reis L, Scherl S, Urken ML. Improving the quality of thyroid cancer care: how does the thyroid cancer care collaborative cross the institute of medicine’s quality chasm? Thyroid. 2014;24(4):615–24.CrossRefGoogle Scholar
  11. 11.
    Lewis C. Editorial: consent to treatment: supreme court discards Bolam principle. Med Leg J. 2015;83:59–61.CrossRefGoogle Scholar
  12. 12.
    Lewis MH, Gohagan JK, Merenstein DJ. The locality rule and the physician’s dilemma: local medical practices vs the national standard of care. JAMA. 2007;297:2633–7.CrossRefGoogle Scholar
  13. 13.
    Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–7.CrossRefGoogle Scholar
  14. 14.
    Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC Cancer Base No. 11. International Agency for Research on Cancer; 2013.
  15. 15.
    La Vecchia C, Malvezzi M, Bosetti C, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136:2187–95. Scholar
  16. 16.
    Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015;47:127–41. Scholar
  17. 17.
    Oh CM, Jung KW, Won YJ, Shin A, Kong HJ, Lee JS. Age-period-cohort analysis of thyroid cancer incidence in Korea. Cancer Res Treat. 2015;47:362–9. Scholar
  18. 18.
    Park S, Oh CM, Cho H, Lee JY, Jung KW, Jun JK, Won YJ, Kong HJ, Choi KS, Lee YJ, Lee JS. Association between screening and the thyroid cancer “epidemic” in South Korea: evidence from a nationwide study. BMJ. 2016;355:i5745. Scholar
  19. 19.
    Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma S, Kuma K, Miyauchi A. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003;13(4):381–7.CrossRefGoogle Scholar
  20. 20.
    Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24:27–34.CrossRefGoogle Scholar
  21. 21.
    Takami H, Ito Y, Okamoto T, Yoshida A. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of endocrine surgeons. World J Surg. 2011;35:111–21.CrossRefGoogle Scholar
  22. 22.
    Takami H, Ito Y, Okamoto T, Onoda N, Noguchi H, Yoshida A. Revisiting the guidelines issued by the Japanese Society of Thyroid Surgeons and Japan Association of endocrine surgeons: a gradual move towards consensus between Japanese and western practice in the management of thyroid carcinoma. World J Surg. 2014;38(8):2002–10.CrossRefGoogle Scholar
  23. 23.
    Pitoia F, Ward L, Wohllk N, Friguglietti C, Tomimori E, Gauna A, Camargo R, Vaisman M, Harach R, Munizaga F, Corigliano S, Pretell E, Niepomniszcze H. Recommendations of the Latin American thyroid society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol. 2009;53(7):884.CrossRefGoogle Scholar
  24. 24.
    Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214. Erratum in: Thyroid. 2010 Jun;20(6):674-5.CrossRefGoogle Scholar
  25. 25.
    Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW. Wiersinga W; European thyroid Cancer taskforce: European consensus for the management of patients with differentiated thyroid cancer of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.CrossRefGoogle Scholar
  26. 26.
    Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341–9.CrossRefGoogle Scholar
  27. 27.
    Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, Pacini F. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol. 2011;165:441–6.CrossRefGoogle Scholar
  28. 28.
    Vaisman F, Momesso D, Bulzico DA, Pessoa CH, Dias F, Corbo R, Vaisman M, Tuttle RM. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol. 2012;77:132–8.CrossRefGoogle Scholar
  29. 29.
    Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American Thyroid Association and Latin American thyroid society risk of recurrence classification systems. Thyroid. 2013;23:1401–7.CrossRefGoogle Scholar
  30. 30.
    Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Dejax C, Toubert ME, Leboulleux S, Ricard M, Benhamou E, Tumeurs de la Thyroïde Refractaires Network for the Essai Stimulation Ablation Equivalence Trial. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366(18):1663–73.CrossRefGoogle Scholar
  31. 31.
    Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366(18):1674–85.CrossRefGoogle Scholar
  32. 32.
    Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, Pacini F. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2(5):356–8. Scholar
  33. 33.
    Brose MS, Smit J, Capdevila J, Elisei R, Nutting C, Pitoia F, Robinson B, Schlumberger M, Shong YK, Takami H. Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Expert Rev Anticancer Ther. 2012;12(9):1137–47. Scholar
  34. 34.
    Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–28.CrossRefGoogle Scholar
  35. 35.
    Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. NEJM. 2015;372(7):621–30.CrossRefGoogle Scholar
  36. 36.
    Sawka A, Rotstein L, Brierley J, et al. Regional differences in opinion on adjuvant radioactive iodine treatment in the United States and Canada. Thyroid. 2007;17(12):1235–42.CrossRefGoogle Scholar
  37. 37.
    Rachinsky I, Rajaraman M, Leslie W, et al. Regional variation across Canadian centers in radiactive iodine administration for thyroid remnant ablation in well-differentiated thyroid cancer diagnosed in 2000–2010. J Thyroid Res. 2016;2016:2867916. Scholar
  38. 38.
    Hall S, Irish J, Groome P, et al. Practice patterns in the management of patients with differentiated thyroid cancer in Ontario Canada 2000–2008. J Otolaryngol Head Neck Surg. 2014;43:29.CrossRefGoogle Scholar
  39. 39.
    Ballal S, Soundararajan R, Garg A, Chopra S, Bal C. Intermediate-risk differentiated thyroid carcinoma patients who were surgically ablated do not need adjuvant radioiodine therapy: long-term outcome study. Clin Endocrinol. 2016;84(3):408–16.CrossRefGoogle Scholar
  40. 40.
    Bal C, Ballal S, Soundararajan R, Chopra S, Garg A. Radioiodine remnant ablation in low-risk differentiated thyroid cancer patients who had R0 dissection is an over treatment. Cancer Med. 2015;4(7):1031–8.CrossRefGoogle Scholar
  41. 41.
    Qaseem A, Snow V, Owens DK, Shekelle P. The development of clinical practice guidelines and guidance statements of the American college of physicians: summary of methods. Ann Intern Med. 2010;153:194–9.CrossRefGoogle Scholar
  42. 42.
    Haymart MR, Muenz DG, Stewart AK, Griggs JJ, Banerjee M. Disease severity and radioactive use for thyroid cancer. J Clin Endo Metab. 2013;98:678–86.Google Scholar
  43. 43.
    Papaleontiou M, Banerjee M, Yang D, Sisson JC, Koenig RJ, Haymart MR. Factor that influence radioactive iodine use for thyroid cancer. Thyroid. 2013;23:219–24.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Ujjal K. Mallick
    • 1
  • Fabián Pitoia
    • 2
  1. 1.Chief Investigator UK National “IoN” and HiLo Trials, Past Clinical Oncologist and Regional Thyroid MDT, Northern Centre for Cancer CareFreeman HospitalNewcastle upon TyneUK
  2. 2.Division of EndocrinologyHospital de Clínicas, University of Buenos AiresBuenos AiresArgentina

Personalised recommendations